Last reviewed · How we verify
Placebo for BCAA
A placebo has no active pharmacological mechanism and produces no direct biological effect beyond the placebo response.
A placebo has no active pharmacological mechanism and produces no direct biological effect beyond the placebo response. Used for Control arm in BCAA supplementation clinical trials.
At a glance
| Generic name | Placebo for BCAA |
|---|---|
| Sponsor | Post Graduate Institute of Medical Education and Research, Chandigarh |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Placebos are inert substances used as controls in clinical trials to measure the effect of expectation and psychological factors on patient outcomes. In this case, it serves as a control comparator for branched-chain amino acid (BCAA) supplementation studies. Any observed effects are attributable to patient expectation, natural disease course, or regression to the mean rather than active drug mechanism.
Approved indications
- Control arm in BCAA supplementation clinical trials
Common side effects
Key clinical trials
- Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC) (PHASE2, PHASE3)
- Tirzepatide in MetALD (PHASE2)
- Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (PHASE3)
- A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque Psoriasis (PHASE3)
- Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) (PHASE2)
- Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis (PHASE2)
- Effects of NAC on Symptoms of CHR Patients (NA)
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: